Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510617-15-00

Enrollment

378

Registered

2024-09-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-metastatic resectable pancreatic cancer

Brief summary

Primary endpoint is overall survival by intention to treat

Interventions

DRUGIrinotecan HCl-trihydraat Accord 20 mg/ml concentraat voor oplossing voor infusie

DRUGOxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

DRUGFolinezuur Sandoz 10 mg/ml

DRUGoplossing voor injectie

DRUGFluorouracil Accord 50 mg/ml

DRUGoplossing voor injectie of infusie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary endpoint is overall survival by intention to treat	—

Countries

Netherlands, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026